Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
LONDON, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced it has filed and mailed a shareholder circular (the “Shareholder Circular”) and related meeting and proxy materials in connection with its upcoming General Meeting of Shareholders (the “General Meeting”) to be held on November 18, 2022 at 2:00 p.m. London time.
- At the General Meeting, shareholders will consider resolutions to remove five of Mereos directors and replace them with five directors nominated by Rubric.
- Mereo recommends that shareholders vote and vote against all of the resolutions to be put to the General Meeting.
- Mereo also today issued the following notice to shareholders, which will accompany the physical mailing of the Shareholder Circular.
- The Shareholder Circular contains, among other information, details regarding procedures for voting at the General Meeting, as well as comprehensive information regarding Mereos engagement with Rubric and perspectives on its resolutions.